-
The BD strategy behind the PD-1 business war
Time of Update: 2021-05-02
cancer (clinical code CheckMate451).
>
After tasting the sweetness of export-oriented BD cooperation, K medicine is also more open in choosing partners (CP), and has successively carried out in-depth bundling
-
Microchip Technology: Cioroni is approved for clinical trial in the treatment of relapsed/refractory SCLC
Time of Update: 2021-05-02
>
>
>
>
>
>
>
>
On April 16, Microchip announced that the company has recently received an approval from
-
Poinsettia subsidiary obtains the registration certificate of pantoprazole sodium for injection
Time of Update: 2021-05-02
, had recently received the "Drug Registration Certificate" for pantoprazole sodium for injection approved and issued by the National Medical Products Administration.
-
Hutchison Pharmaceuticals announces that it has received US$100 million equity investment from Baring Asia Investment Fund
Time of Update: 2021-05-02
funds through private placement, at an issue price of US$30. 5 per American depositary share.
>
It is understood that Hutchison Medicine obtained all funds equivalent to 3,278,689 American Depositary
-
Mycophenolate sodium enteric-coated tablets, a subsidiary of Hengrui Pharmaceuticals, was approved for listing
Time of Update: 2021-05-02
On April 6, Hengrui Medicine issued an announcement stating that its subsidiary Chengdu Shengdi had recently received the "Drug Registration Certificate" for mycophenolate sodium enteric-coated tablets approved and issued by the State Food and Drug Administration.
-
Yangtze River Pharmaceutical's "Rigofinil Tablets" Launched on the First Domestic Newspaper
Time of Update: 2021-05-02
On March 24, 2013, the original CFDA approved its listing for the treatment of metastatic colorectal cancer (mCRC) that had previously received fluorouracil, oxaliplatin, and irinotecan-based chemotherapy and anti-EGFR therapy (RAS wild-type).
-
Microchip's "Cioroni Capsule" launches Phase III clinical trial for small cell lung cancer
Time of Update: 2021-05-02
Recently, the Insight database revealed that Microchip Bio-Sioroni Capsules has launched a Phase III clinical trial for the treatment of small cell lung cancer that has progressed or recurred after a 2-line system of chemotherapy.
-
National Class 1
Time of Update: 2021-05-02
As the first domestic innovative epothilone anti-tumor drug independently developed by Huahao Zhongtian, the launch of Utidrolone provides an important new treatment option for Chinese patients with advanced breast cancer.
-
Haisco HSK29116 obtained clinical approval in bulk
Time of Update: 2021-05-02
It is an oral Protac small molecule anti-tumor drug that can selectively block BTK kinase activity and interfere with B cell development by regulating signal pathways, thereby controlling various B cell malignant tumors.
-
Original | General Tasks of Tumor Treatment
Time of Update: 2021-04-29
Although there are some preclinical models, including PDX from patients with metastasis and highly metastatic mouse tumors such as 4T1 that induce cancer, in general, they cannot reliably simulate the process of clinical tumor metastasis.
-
Advanced Science | Shanghai Jiaotong University Duan Yourong/Lin Houwen/Liao Hongze The development of new protein inhibitors has important reference significance for the control of tumor blood-borne metastasis
Time of Update: 2021-04-27
This study generally demonstrates the feasibility of using DR6/APP interaction to regulate transendothelial migration of blood-borne tumor cells, and provides PEG-tAHP-DRI as a DR6/APP interaction for the development of anti-blood-borne metastasis therapies A novel and promising inhibitor.
-
Pfizer said an oral new crown treatment drug has entered clinical trials
Time of Update: 2021-04-27
This is the world's first oral new crown treatment drug to enter clinical trials.
-
Luoxin Pharmaceutical Subsidiary Omeprazole Sodium for Injection Passed the Consistency Evaluation
Time of Update: 2021-04-27
The omeprazole sodium for injection developed by Shandong Luoxin was first approved for marketing in 2005.
-
Luye Pharma's Class 1 new drug Ansufaxine Hydrochloride Sustained-Release Tablets reached the preset end point in Phase III clinical trials
Time of Update: 2021-04-27
The China Phase III clinical trial of LY03005 is a multi-center, randomized, double-blind, placebo-controlled study to verify the effectiveness and safety of LY03005 in the treatment of depression.
-
China's first RET inhibitor, Cornerstone Pharmaceuticals, pratinib approved
Time of Update: 2021-04-27
>It is reported that Pratinib is China's first approved RET inhibitor. >Pratinib is a potent and selective RET inhibitor developed by Blueprint Medicines under the trade name GAVRETO™.
-
Flt3 inhibitor AML produces CR: talk about off-target activity
Time of Update: 2021-04-27
Drug source analysisDrug source analysisLuxe was originally developed as a reversible BTK inhibitor and its main use is chronic leukemia, but so far it is still a substitute goalkeeper in this arena.
-
The targeted anticancer drug Pepaxto is included in the NCCN clinical practice guidelines for multiple myeloma in the United States
Time of Update: 2021-04-27
Recently, the company announced that its targeted anticancer drug Pepaxto (melphalan flufenamide, also known as melflufen) has been included in the National Cancer Comprehensive Network (NCCN) clinical practice for multiple myeloma guide.
-
Chengdu Shengdi Pharmaceutical's Mycophenolate Sodium Enteric-coated Tablets for the imitation of Category 4 applications will be approved soon
Time of Update: 2021-04-27
Medical Network News on March 23 A few days ago, Chengdu Shengdi Pharmaceutical entered the administrative examination and approval stage with mycophenolate sodium enteric-coated tablets for imitation of category 4 applications.
-
Hutchison Pharmaceuticals announces that it has received US$100 million equity investment from Baring Asia Investment Fund
Time of Update: 2021-04-24
On April 8, Hutchison Pharma announced that it had reached a final agreement with Baring Asia Investment Fund to issue 100 million US dollars of new shares to Baring Asia’s related funds
-
CStone's KIT/PDGFRA mutant kinase inhibitor avatinib was approved in China
Time of Update: 2021-04-24
Today, China’s National Food and Drug Administration (NMPA) drug approval certificate pending information shows that the KIT and PDGFRA mutant kinase inhibitor avapritinib (previously used Chinese name: apotinib) declared by CStone Pharmaceuticals is already available.
